Day One Biopharmaceuticals (DAWN) director’s equity cashed out in Servier merger
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Day One Biopharmaceuticals director Natalie C. Holles reported the cash-out of all remaining equity awards in connection with the Servier acquisition. On April 23, 2026, her 57,310 shares of common stock, 15,000 restricted stock units, and multiple stock option grants were disposed of to the issuer at the merger closing.
Under the merger completed at an Offer Price of $21.50 per share, each common share was purchased or converted into the right to receive cash, and each stock option and RSU was canceled for a cash payment based on the merger consideration, less any required taxes. Following these transactions, the Form 4 shows no remaining common stock or derivative holdings for Holles.
Positive
- None.
Negative
- None.
Insights
Holles’ Form 4 reflects a routine merger cash-out of equity, not open-market selling.
The filing shows Natalie C. Holles disposed of common shares, RSUs, and fully vested stock options to Day One Biopharmaceuticals when Servier’s acquisition closed at an Offer Price of $21.50 per share. This is standard treatment in a cash merger.
Footnotes explain that unvested options and RSUs became fully vested immediately before closing, then all awards were canceled for cash equal to the merger consideration (or the spread for options), less taxes. With total holdings shown as zero afterward and no open-market trades, this Form 4 mainly documents deal mechanics rather than a directional view on the stock.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Holles Natalie C.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy Common Stock) | 40,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 40,300 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 28,700 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 37,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 32,335 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 22,500 | $0.00 | -- |
| Disposition | Restricted Stock Unit (RSU) | 15,000 | $0.00 | -- |
| Disposition | Common Stock | 57,310 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 0 shares (Direct, null);
Restricted Stock Unit (RSU) — 0 shares (Direct, null);
Common Stock — 0 shares (Direct, null)
Footnotes (1)
- On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and Servier S.A.S., a French societe par actions simplifiee, solely as a guarantor, entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement, or (y) automatically converted into the right to receive the Offer Price (the "Merger Consideration"), net to the seller in cash, without interest, and subject to applicable withholding taxes, on the terms and conditions set forth in the Merger Agreement. The options are fully vested. Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration (or, in the case of stock options, the difference between the Merger Consideration and the applicable per share exercise price), less any applicable withholding taxes. The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.
Key Figures
Offer Price per share: $21.50 per share
Common shares disposed: 57,310 shares
RSUs disposed: 15,000 units
+3 more
6 metrics
Offer Price per share
$21.50 per share
Cash consideration for each common share in the merger
Common shares disposed
57,310 shares
Common Stock held by Natalie Holles canceled at closing
RSUs disposed
15,000 units
Restricted Stock Units converted to cash at merger effective time
Options at $7.01
22,500 options at $7.01
Fully vested stock options canceled for cash spread vs. merger price
Options at $8.99
208,835 options at $8.99
Multiple grants of stock options at $8.99 exercise price canceled for cash
Post-transaction holdings
0 shares / 0 derivatives
Form 4 totals following merger-related dispositions
Key Terms
Agreement and Plan of Merger, Merger Consideration, restricted stock unit ("RSU"), Offer Price, +1 more
5 terms
Agreement and Plan of Merger regulatory
"entered into an Agreement and Plan of Merger (the "Merger Agreement")"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"automatically converted into the right to receive the Offer Price (the "Merger Consideration")"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
restricted stock unit ("RSU") financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
Offer Price financial
"purchased for $21.50 per share (the "Offer Price"), net to the seller in cash"
The offer price is the amount per share that a company or underwriter sets when selling new stock or bonds to investors, like the price tag on an item in a store. It matters because it determines how much investors must pay, shapes the initial market value of the security, and influences whether demand will be strong or weak — which affects early trading performance and potential returns.
stock option financial
"each stock option and restricted stock unit was canceled and converted into the right to receive an amount in cash"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
What insider transaction did DAWN director Natalie Holles report?
Natalie C. Holles reported disposing of common stock, restricted stock units, and stock options to Day One Biopharmaceuticals when Servier’s merger closed. All equity awards were canceled in exchange for cash consideration tied to the merger terms.
What happened to Natalie Holles’ DAWN stock options in the merger?
Holles’ outstanding stock options became fully vested immediately before the merger and were then canceled. Each option was converted into a cash payment equal to the merger consideration minus the option’s exercise price, less any required tax withholding at closing.
What was the treatment of DAWN restricted stock units held by Natalie Holles?
All unvested restricted stock units became fully vested immediately prior to the merger’s effective time and were then canceled. Each RSU converted into the right to receive cash equal to one share’s merger consideration, reduced by applicable withholding taxes, instead of delivering shares.